Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of [177Lu]-NeoB in GRPR-positive advanced solid tumors
NL-OMON54819Phase 1Recruiting
- Sponsor
- Advanced Accelerator Applications
- Start
- May 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of neobomb1 in breast cancer, prostate cancer (PCa), gastrointestinal stromal tumor (GIST) and 3 more (5 arms), sponsored by Advanced Accelerator Applications. Primary endpoints: Maximum tolerated dose and/or recommended phase II dose, Disease control rate and 4 more. Started May 2022; status: recruiting.
02
Drugs
neobomb1
03
Conditions
breast cancerprostate cancer (PCa)gastrointestinal stromal tumor (GIST)bronchial carcinomaglioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON54819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54819.